Actavis Laboratories FL, Inc.

Actavis Laboratories FL, Inc. is a pharmaceutical company based in Davie, Florida, specializing in the importation and distribution of finished pharmaceutical formulations. Established on November 21, 2002, the company operates as a subsidiary of Teva Pharmaceuticals, a global leader in generic and specialty medicines. Actavis Laboratories FL, Inc. plays a significant role in the United States pharmaceutical distribution network, focusing on sourcing and supplying a diverse range of generic medications to meet market demands.

The company's primary distribution center is located at 4955 Orange Drive, Davie, Florida 33314. This facility serves as the central hub for logistics and distribution operations, ensuring efficient delivery of pharmaceutical products across the United States. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Actavis Laboratories FL, Inc. is known for its robust distribution network, facilitating timely and reliable supply to various healthcare providers nationwide.

Actavis Laboratories FL, Inc. functions as a pharmaceutical importer and distributor within the United States market. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of generic medications to meet the needs of healthcare providers and patients. This role is crucial in enhancing the accessibility and affordability of essential medicines across the country.

Actavis Laboratories FL, Inc. demonstrates a high degree of supplier concentration, with a total import value of $12.3 million USD from India, comprising 360 shipments. All these imports are sourced from a single supplier, WATSON PHARMA PRIVATE LIMITED, indicating a strategic partnership or exclusive distribution agreement. This single-source dependency may present risks related to supply chain disruptions or changes in supplier dynamics. However, the consistent volume and frequency of shipments suggest a stable and reliable relationship between Actavis Laboratories FL, Inc. and WATSON PHARMA PRIVATE LIMITED.

The resilience of Actavis Laboratories FL, Inc.'s supply chain is closely tied to its exclusive sourcing arrangement with WATSON PHARMA PRIVATE LIMITED. The lack of backup suppliers and the concentration on a single supplier may expose the company to risks such as supply interruptions or geopolitical issues affecting trade routes. Additionally, the limited diversity in imported formulations could impact the company's ability to adapt to changing market demands or regulatory requirements. Ensuring the regulatory compliance of WATSON PHARMA PRIVATE LIMITED, including adherence to Good Manufacturing Practices (GMP), is essential to maintain the quality and reliability of the supply chain.

The sourcing pattern of Actavis Laboratories FL, Inc. indicates a strong reliance on WATSON PHARMA PRIVATE LIMITED, which may offer benefits such as favorable pricing and consistent product quality. However, this concentration also poses potential risks, including vulnerability to supply chain disruptions and limited flexibility in product offerings. For Indian exporters seeking to become alternative suppliers, this presents an opportunity to diversify Actavis Laboratories FL, Inc.'s supplier base by offering competitive pricing, high-quality products, and the ability to meet regulatory standards required for the U.S. market.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs, including generics, ensuring they meet the necessary standards before entering the U.S. market.

Import licensing requirements for pharmaceutical products entering the United States are stringent. Foreign manufacturers must register with the FDA and obtain an establishment registration number. Additionally, they must comply with the FDA's Good Manufacturing Practice (GMP) regulations, which are aligned with international standards such as EU GMP, WHO GMP, and PIC/S. These certifications ensure that manufacturing processes meet the required quality standards. Wholesale distributors like Actavis Laboratories FL, Inc. must also obtain appropriate state licenses to operate legally within the U.S.

Pharmaceutical products imported into the United States must undergo batch testing to verify their identity, strength, quality, and purity. Stability studies are conducted to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing information in English, detailing dosage instructions, active ingredients, and any necessary warnings. Serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the supply chain.

Between 2024 and 2026, the FDA has implemented several policy changes affecting pharmaceutical imports from India. These include enhanced scrutiny of manufacturing facilities, stricter enforcement of GMP compliance, and increased inspections to ensure product quality. Additionally, there has been a focus on improving the efficiency of the drug approval process for generic medications, aiming to expedite market entry while maintaining safety standards.

Actavis Laboratories FL, Inc. focuses on importing pharmaceutical products in the Central Nervous System (CNS) & Psychiatric, Respiratory, and Cardiovascular therapeutic categories. This strategic focus aligns with market demand for treatments in these areas, addressing prevalent health conditions and contributing to the company's competitive positioning in the U.S. market. The high import value of Alprazolam, a CNS & Psychiatric medication, underscores the significant demand for such products.

Actavis Laboratories FL, Inc. employs a sourcing strategy that emphasizes high-volume imports of specific generic medications, particularly those with established efficacy and safety profiles. The company's preference for sourcing from India is likely due to the country's robust pharmaceutical manufacturing capabilities, cost-effectiveness, and adherence to international quality standards. This approach enables Actavis Laboratories FL, Inc. to offer a reliable supply of essential medications to the U.S. market.

Based on its product mix, Actavis Laboratories FL, Inc. serves the wholesale distribution segment of the United States pharmaceutical market. By importing and distributing generic medications, the company plays a crucial role in supplying healthcare providers, including retail pharmacies, hospitals, and clinics, with affordable and effective treatment options. This positioning supports the broader healthcare system by enhancing access to necessary medications.

There is a realistic opportunity for new Indian suppliers to engage with Actavis Laboratories FL, Inc. by offering high-quality generic medications that meet FDA standards. Gaps in Actavis Laboratories FL, Inc.'s current sourcing include a limited supplier base and a narrow range of imported formulations. Indian exporters can capitalize on these gaps by providing diverse product offerings, competitive pricing, and ensuring compliance with regulatory requirements to become viable alternative suppliers.

Indian exporters aiming to supply Actavis Laboratories FL, Inc. and the U.S. market must obtain FDA registration and comply with GMP standards recognized by the FDA. Additionally, they must ensure that their products meet FDA labeling requirements and pass necessary quality control tests. Maintaining certifications such as EU GMP, WHO GMP, or PIC/S can enhance credibility and facilitate the approval process.

Indian exporters should initiate contact with Actavis Laboratories FL, Inc. by presenting their product portfolios, emphasizing compliance with FDA standards, and demonstrating the ability to meet quality and supply requirements. Participating in industry trade shows and establishing connections through professional networks can also be effective strategies. Understanding the regulatory filing process and preparing for timely submissions are crucial steps, with expectations for a lead time of several months to complete the approval process.